(BYSI) – Company Press Releases
-
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
-
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
-
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
-
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumor
-
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient De
-
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
-
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
-
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
-
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
-
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
-
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
-
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
-
BeyondSpring Files 2022 Annual Report on Form 20-F
-
BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results
-
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
-
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules
-
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences
-
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
-
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
-
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual
-
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting
-
Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing
-
BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
-
BeyondSpring Files 2021 Annual Report on Form 20-F
-
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
-
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
-
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
-
BeyondSpring Announces Organizational Streamlining
-
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
-
BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
-
BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)
-
BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
-
BeyondSpring Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
-
BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors
-
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoi
-
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical D
-
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EG
-
BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
-
BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
-
BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress
-
BeyondSpring to Participate in the Upcoming September Conferences
-
BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021
-
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patien
-
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
-
BeyondSpring CEO Dr. Lan Huang Named to PharmaVOICE 100 Most Inspiring People in Life Sciences
-
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC)
-
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
Back to BYSI Stock Lookup
